Program
itepekimab
Also written as “Itepekimab (SAR440340)”, “REGN3500” and “Itepekimab SAR440340”.
Its studies are mostly in Nasal Polyps · Pulmonary Disease, Chronic Obstructive · Asthma · Dermatitis, Atopic · Bronchiectasis, led by 2 companies.
Drug pageItepekimab: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofiits history only | 123 open or running | phase 3since Dec 30, 2020 | Dec 15, 2017 | Feb 17, 2027phase 3 · NCT07424144 |
| Regeneron Pharmaceuticalsits history only | 50 open or running | phase 2since Nov 7, 2018 | Oct 25, 2016 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 1 study since Oct 25, 2016.
- Dec 19, 2016Phase 1 study in AsthmaRegeneron Pharmaceuticals · NCT02999711 · 23 enrolled · United Kingdom
- Apr 4, 2017Phase 1 study in AsthmaRegeneron Pharmaceuticals · NCT03112577 · 32 enrolled · United States, United Kingdom
- Dec 15, 2017Sanofi’s first study: phase 2 study in AsthmaNew to SanofiSanofi · NCT03387852 · 296 enrolled · United States, Argentina, Chile and more
- May 17, 2018Phase 2 study in Pulmonary Disease, Chronic ObstructiveSanofi · NCT03546907 · 343 enrolled · United States, Argentina, Australia and more
- Nov 7, 20182 phase 2 studies in Dermatitis, AtopicRegeneron Pharmaceuticals · NCT03736967, NCT03738423
- Dec 9, 2019Named itepekimabINNProposed as its International Nonproprietary Name in WHO's List 122 · before, REGN3500, SAR440340
- Dec 30, 2020Phase 3 study in Pulmonary Disease, Chronic ObstructiveSanofi · NCT04701983 · 1,127 enrolled · United States, Argentina, Bulgaria and more
- Feb 8, 2021Phase 3 study in Pulmonary Disease, Chronic ObstructiveSanofi · NCT04751487 · 1,234 enrolled · United States, Argentina, Brazil and more
- Apr 6, 2022Phase 2 study in Pulmonary Disease, Chronic ObstructiveSanofi · NCT05326412 · 49 enrolled · United States, Belgium, Brazil and more
- Jan 5, 2024Phase 3 study in Pulmonary Disease, Chronic ObstructiveSanofi · NCT06208306 · 669 enrolled · United States, Argentina, Brazil and more
- Feb 20, 2024Phase 2 study in BronchiectasisSanofi · NCT06280391 · 314 enrolled · United States, Argentina, Brazil and more
- Nov 12, 2024Phase 2 study in Chronic Rhinosinusitis Without Nasal PolypsSanofi · NCT06691113 · 66 enrolled · United States, Argentina, Belgium and more
- Feb 14, 20252 phase 3 studies in Chronic Rhinosinusitis With Nasal PolypsSanofi · NCT06834360, NCT06834347
- Feb 13, 2026Phase 3 study in Chronic Rhinosinusitis With Nasal PolypsSanofi · NCT07424144 · 59 enrolled · United States, Argentina, Australia and more
- Mar 16, 2026Phase 3 study in Chronic Rhinosinusitis With Nasal PolypsSanofi · NCT07484230
Ahead
- Feb 17, 2027Primary completion: phase 3 study in Chronic Rhinosinusitis With Nasal PolypsSanofi · NCT07424144
TargetBeta
“Interleukin-33 inhibitor”ChEMBL 37, by rule
Other programs on IL33
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| GSK3862995B | GlaxoSmithKline | phase 2 | 5 |
| ompekimig | Pfizer | phase 2 | 3 |
| HXN-1013rule | Helixon Biotechnology (Suzhou) | phase 1 | 1 |
| HY6725rule | Newsoara Biopharma | phase 1 | 1 |
Studies
All 17 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07484230Chronic Rhinosinusitis With Nasal Polyps | 3 | Withdrawn | Sanofi | Oct 20, 2027 | 0 |
| NCT07424144Chronic Rhinosinusitis With Nasal Polyps · United States, Argentina, Australia and more | 3 | Active, not recruiting | Sanofi | Feb 17, 2027 | 59 |
| NCT06834360Chronic Rhinosinusitis With Nasal Polyps · United States, Argentina, Australia and more | 3 | Active, not recruiting | Sanofi | Sep 24, 2026 | 216 |
| NCT06834347Chronic Rhinosinusitis With Nasal Polyps · United States, Argentina, Austria and more | 3 | Active, not recruiting | Sanofi | Sep 23, 2026 | 231 |
| NCT06691113Chronic Rhinosinusitis Without Nasal Polyps · United States, Argentina, Belgium and more | 2 | Completed | Sanofi | Mar 31, 2026 | 66 |
| NCT06280391Bronchiectasis · United States, Argentina, Brazil and more | 2 | Completed | Sanofi | Sep 16, 2025 | 314 |
| NCT06208306Pulmonary Disease, Chronic Obstructive · United States, Argentina, Brazil and more | 3 | Completed | Sanofi | Sep 10, 2026 | 669 |
| NCT05326412Pulmonary Disease, Chronic Obstructive · United States, Belgium, Brazil and more | 2 | Completed | Sanofi | Mar 5, 2025 | 49 |
| NCT04751487Pulmonary Disease, Chronic Obstructive · United States, Argentina, Brazil and more | 3 | Completed | Sanofi | Apr 21, 2025 | 1,234 |
| NCT04701983Pulmonary Disease, Chronic Obstructive · United States, Argentina, Bulgaria and more | 3 | Completed | Sanofi | Apr 11, 2025 | 1,127 |
| NCT03738423Dermatitis, Atopic · United States, Australia, Canada and more | 2 | Terminated | Regeneron Pharmaceuticals | Mar 13, 2020 | 129 |
| NCT03736967Dermatitis, Atopic · United States, Belgium, Czechia and more | 2 | Terminated | Regeneron Pharmaceuticals | Mar 13, 2020 | 206 |
| NCT03546907Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more | 2 | Completed | Sanofi | Oct 3, 2019 | 343 |
| NCT03387852Asthma · United States, Argentina, Chile and more | 2 | Completed | Sanofi | Mar 21, 2019 | 296 |
| NCT03112577Asthma · United States, United Kingdom | 1 | Completed | Regeneron Pharmaceuticals | Mar 20, 2019 | 32 |
| NCT02999711Asthma · United Kingdom | 1 | Completed | Regeneron Pharmaceuticals | Aug 30, 2018 | 23 |
| NCT02958436Healthy Volunteers · Belgium | 1 | Completed | Regeneron Pharmaceuticals | Jun 18, 2017 | 40 |
How it is read
Names in the registry
- “Itepekimab (SAR440340)”, 7 entries
- “REGN3500”, 5 entries
- “Itepekimab SAR440340”, 3 entries
- “SAR440340”, 2 entries
Conditions, from the studies’ own filings
- Nasal Polyps, 5 studies
- Pulmonary Disease, Chronic Obstructive, 5 studies
- Asthma, 3 studies
- Dermatitis, Atopic, 2 studies
- Bronchiectasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.